Five Questions About Protopic (tacrolimus...(vailable in two concentrations: 0.1% an...)

Date:8/3/2009

vailable in two concentrations: 0.1% and 0.03%. Either concentration can be used in adults, while only the 0.03% concentration is indicated for children between the ages of 2 and 15. Protopic should not be used in children under the age of 2.(5)

What clinical studies were conducted to support the approval of Protopic?

Three randomized, double-blinded, clinical studies using un-medicated ointment were conducted to support approval of Protopic and demonstrate its safety and effectiveness in treating adults and children with moderate to severe eczema.(7,8,9)

In the adult studies of 632 patients, a significantly greater number of patients achieved at least a 90% or better improvement of their eczema with either the 0.1% or 0.03% concentrations of Protopic, based on their physician's global assessment, at 12 weeks compared to those patients who were treated with an un-medicated ointment.(8)

Similarly, a study of 351 patients ages 2 to 15 showed that a significantly greater number of patients had at least 90% or more improvement with Protopic, based on physician global assessment, compared with an un-medicated ointment.(9) Only Protopic Ointment 0.03% is indicated for children aged 2 to 15 years.

These clinical trials also showed that both pediatric and adult eczema patients who used Protopic had an itch reduction 5 times greater than those who used an un-medicated ointment.(8,9)

What is the important safety information for Protopic?

Protopic should not be used by patients who are allergic to any of its ingredients. The most common side effects with the use of Protopic are sensation of skin burning or itching, flu-like symptoms and headaches. Patients using Protopic should avoid natural or artificial sunlight (sun lamps
'/>"/>

SOURCE Astellas Pharmaceuticals Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Bringing a New Rhythm to Cardiology Workflow: Siemens Demonstrates Answers to Cardiologys Toughest Questions
2. New Study Raises Questions About Prostate Cancer Therapies Targeting Insulin-Like Growth Factor Receptor
3. NeurogesX Responds to EMEAs Day 120 Questions
4. Americans United for Life: Obamas Disbanding Bioethics Council Raises Troubling Questions
5. MultiVu Video Feed: Allergan, Inc. Partners With "Project Runway" Designer Kara Saun and Gen Art Fresh Faces In Fashion to Raise Awareness About Excessive Underarm Sweating
6. Stevens researchers provide new information about mass spectrometry
7. Varian Medical Systems Sponsors Special Broadcast of The Group Room(R), a Live Radio Talkshow About Cancer
8. Actress Aida Turturro Tells Americans to Start Now to Talk With Their Healthcare Provider About Taking Control of Their Diabetes
9. U.S. District Court Decision About Eisais Legal Action Over Aricept ODT(R) ANDA Filing
10. Bio-Identical Hormone Menopause Doctor Responds to Recent FDA News About Estriol
11. Montana State University lab gives early warnings about biological invaders